Research publications

Oncology

GBR 1302

Dual targeting of CD3 and HER2 using GBR 1302, a BEAT® antibody, leads to potent killing of HER2 overexpressing target cells

Presented By:

Keystone Symposia on Molecular and Cell Biology 2015
View

Oncology

GBR 1302

Upstream process development for GBR 1302, a Bispecific Antibody Based on Glenmark's Proprietary BEAT® (Bispecific Engagement By Antibodies Based on T Cell Receptor) Format

Presented By:

ESCAT 2015
View

Oncology

GBR 1302

GBR1302-BEAT®bispecificantibody for the treatment of HER2 positive cancers

Presented By:

PEGS 2014
View

Pain

GRC 27864

Novel, selective & orally active Microsomal Prostaglandin E Synthase-1 Inhibitor for potential treatment of Arthritic Pain

Presented By:

Inflammation Research Association - 17th International Conference
View

Pain

GRC 27864

GRC 27864 - A novel, selective & orally active Microsomal Prostaglandin E Synthase 1 (mPGES-1) inhibitor for potential treatment of arthritic pain

Presented By:

World Pharma congress, May 21-23, 2014
View

Pain

GBR 830

GBR 830: An antagonistic anti-human OX40 mAb with potent suppressive effect on pathological immune responses

Presented By:

PEGS 2014
View